At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 108 enrolled
Drug / intervention
2:1 EPA/DHA +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Omega 3 for Comorbid Depression and Heart Failure Treatment
In Brief
A Phase 3 clinical trial evaluating 2:1 EPA/DHA, High EPA, and 1 other intervention for Depression. Completed, enrolled 108 participants across 3 sites.
Detailed Summary
Omega 3 supplements will improve depressive symptoms to a greater extent than placebo in heart failure patients with moderate to severe major depressive disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 2014
Enrollment StartMay 2014
Primary CompletionMay 2016
Study CompletionDec 2016
TodayJul 2026
First PostedFeb 7, 2014
Enrollment StartMay 1, 2014
Primary CompletionMay 19, 2016
Study CompletionDec 2, 2016
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 12.4 years ago
Interventions
2:1 EPA/DHAdrug
400 Eicosapentaenoic acid/200 docosahexaenoic acid fish oil 2 grams
High EPAdrug
Placeboother